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Aim: To investigate whether there is a signiﬁcant relationship between an increased
frequency of exacerbations and the rate of forced expiratory volume in 1 s (FEV1) decline
in COPD patients.
Methods–measurements: About 102 COPD patients (44 smokers, 58 ex-smokers) partici-
pated in a 3-year prospective study. Exacerbations were identiﬁed as worsening of
patient’s respiratory symptoms as recorded on diary cards. Spirometry was performed
every 6 months. The effect of frequent exacerbations on lung function was investigated
using random effects models.
Results: The median (mean(95% CI)) annual exacerbation rate was 2.85 (3.1 (2.7–3.6)).
Patients with an annual exacerbation rate over the median rate had signiﬁcantly lower
baseline post-bronchodilation FEV1(%pred), higher MRC dyspnoea score and chronic cough
compared to patients who had an annual exacerbation rate less than the median. The
average annual rate of FEV1(%pred), adjusted for smoking decline (DFEV1), was found
signiﬁcantly increased in frequent compared to infrequent exacerbators (P ¼ 0:017). The
highest DFEV1 was observed in smokers frequent exacerbators and a signiﬁcant interaction
between exacerbation frequency and DFEV1 was also observed in ex-smokers.
Conclusions: Our ﬁndings suggest that an increased frequency of exacerbations is
signiﬁcantly associated with FEV1 decline even in ex-smokers. Thus, smoking and frequent
exacerbations may have both negative impact on lung function. Smoking cessation and
prevention of exacerbations should be a major target in COPD.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
392433; fax: +30 81 542650.
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In COPD, exacerbations caused mainly by infections of the
tracheobronchial tree or inhalation of toxic gases,1 are an
important characteristic of the disease. During an exacer-
bation a remarkable worsening of a patient’s baseline
symptoms is observed. COPD exacerbations are the major
cause of physician visits and hospital admissions associated
with acute respiratory failure, causing premature mortality
as well as a worsening of the quality of life.1 Furthermore,
the number of past exacerbations has been related both to
the risk of future recurrent exacerbations and to relapse
following treatment.2 Thus, frequent exacerbations fol-
lowed by incomplete recovery may be an important risk
factor of lung function decline.3 However, the inﬂuence of
exacerbations on the progression of the COPD has not been
well established.4–6
The British Hypothesis, proposed in the 1960s, was that
repetitive chest infections or chronic airway infection might
be the cause of airway obstruction. This hypothesis was
tested in two longitudinal studies, the conclusions of which
were that exacerbations had no effect on the annual rate of
change of FEV1.
4,5 However, the landmark study of Fletcher
and Peto4 was performed only in patients with mild COPD.
Other studies on lung function decline have come to the
opposite conclusion. Kanner et al.7 found an accelerated
rate of FEV1 decline due to lower respiratory illnesses in
smokers with mild COPD. Donaldson et al.8 reported a
relation between exacerbations and lung function decline in
32 COPD patients. The same group also reported an
incomplete recovery of lung function in 7% of COPD
patients.3 In this setting, questions still remain due to small
number of carefully designed studies of appropriate patients
with varying disease severity.
Our primary aim in this study is to investigate whether an
increased frequency of exacerbations is associated with an
accelerated rate of FEV1 decline in both smokers and ex-
smokers with COPD.
Methods
Patients
This investigation was a 3-year prospective study, incorpor-
ating a run-in period and outpatient clinic visits, scheduled
every 3 months. Consecutive sampling was used to recruit
patients with a diagnosis of COPD according to the GOLD
deﬁnition,9,10 who attended the respiratory outpatient
clinic at Chania General Hospital on the island of Crete,
Greece, between June 2002 and October 2002. A history of
bronchial asthma or other respiratory disease and contin-
uous use of systemic steroids more than 30 days in the
previous year were used as exclusion criteria. One hundred
and six patients agreed to participate. Seventy-three
patients were continuously being taken care of at the clinic
and of 33 patients referred to the clinic for ﬁrst time during
the recruitment period and fulﬁlled inclusion criteria. The
study was approved by the ethics committee of the local
health authority and the patients provided their consent.
At recruitment participants provided responses to ques-
tions related to smoking history, respiratory symptoms andsigns, MRC (4-point scale) and current medication use.11,12
Smoking status was veriﬁed by exhaled CO at each visit.13 A
run-in period of 4 weeks following recruitment was used to
ensure that all patients had been free of an acute
exacerbation and had not received antibiotics or short
courses of systemic corticosteroids over the same period.
Four subjects were withdrawn during the run-in period. The
remaining 102 patients were reviewed for a total follow-up
of 3 years.
Spirometry
Every 6 months post-bronchodilation spirometry was per-
formed following premedication with 200 mg salbutamol via
metred-dose inhaler, according to standardized guidelines
guidelines,14 using a computerised system (Lab, 2.12;
Jaeger; Wuerzburg, Germany). Attention was taken on the
day that the spirometry was performed, the subject was
free of an exacerbation; otherwise the test was postponed
until recovery.
Deﬁnition of COPD exacerbation
The deﬁnition of an exacerbation was based on criteria
described previously by Anthonisen et al.15 requiring either,
increase of at least two major respiratory symptoms
(dyspnoea, sputum amount, and sputum purulence) or,
increase of one major symptom in addition to at least one
minor symptom (wheeze, cough, fever, nasal discharge, sore
throat), for at least two consecutive days. The ﬁrst day with
increased symptoms was taken as the onset of the
exacerbation. Following an exacerbation, patients were
required to have a 2-week period (recovery period) with the
same or less symptoms as those present before the start of
an exacerbation before another exacerbation was studied.
Monitoring of exacerbation
A patient directed diary card and hospital-outpatient clinic
data were used to identify exacerbations.
Diary card: The development of the diary card was based
in previously used diary card16 following accepted princi-
ples.15 Accordingly, all patients were instructed to record,
at the end of each day, any increase in major and minor
symptoms with regard to the last 24 h. Patients recorded
changes in their symptoms using a binary coded system. For
each symptom, two options were available on the diary
card: either increased perception/new onset or not.
Consequently, they were instructed to mark the correspond-
ing area on the diary card, when they perceived an increase
over their normal, stable condition in chronic symptoms or
symptoms of new onset, otherwise they had to mark the
area of ‘‘no increase perception/no new onset’’.
Patients were seen and diary cards were collected in
scheduled outpatient clinic visits every 3 months. Patients
were also instructed to call three members (D.M., A.D.,
E.N.) of the medical team and to attend unscheduled visits
whenever they noticed deterioration in symptoms. In
these cases, patients were assessed within 48. Their
symptoms were validated and exacerbations were diagnosed
according to Anthonisen’s criteria and termed as ‘‘reported
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ment9 was used for individual exacerbation treatment.
The diary symptom card was checked for repeatability
and accuracy. Brieﬂy, a member of the medical team
(AD)—blinded to patient’s progress—visited 25 patients,
randomly selected, thrice in each year and administered a
symptoms-questionnaire identical to diary cards, with
regard to the last 24 h. Consequently, the correlation
between questionnaire and diary card was evaluated for
all items. Signiﬁcant correlations were found in all items;
the lowest correlation was found in nasal discharge item
(r ¼ 0.74, P ¼ 0:001). Additionally, 25 patients randomly
selected, were especially instructed to notify the medical
centre when they had increased symptoms. These patients
were seen on the same day and consequently on the 7th,
14th, 21st, 30th day by a member of the medical team (EN)
who administered the above-mentioned questionnaire. This
procedure was repeated until 75 cases of exacerbation were
available for assessment. The agreement between ques-
tionnaire and diary card as to whether an exacerbation was
ended or not, was 88%.
Medical records: Exacerbations where no diary card
symptoms were recorded were identiﬁed by questioning
the patients about their symptoms when at the clinic visits
or, or by reviewing the outpatient clinic and admissions
medical records every 6 months.
Exacerbation rate
The total number of exacerbations was obtained by adding
the number of exacerbations recorded in the diary cards to
the number of exacerbations identiﬁed in the medical
records that were not recorded in the cards (Fig. 1). The
annual rate for each patient was calculated by dividing the
total number of exacerbations by the number of days
participated in the study and multiplying by 365.
Classiﬁcations
Patients were grouped into two categories according to the
annual rate of total number of exacerbations experienced.
Those experiencing more than the median annual exacer-
bation rate were termed ‘‘frequent exacerbators’’ whereas
these with fewer than the median were considered
‘‘infrequent exacerbators’’. This classiﬁcation scheme was
used in previous studies of similar design.8 Each of the two
above categories were then classiﬁed into two subgroups,
current or ex-smoker.Figure 1 Registration characteristics of exacerbations in this
study.Statistical analysis
Random effects modelling (REM or the multilevel model
for change) was used to investigate the possible rela-
tionship between exacerbation frequency and lung
function decline. REM is the most suitable method for
estimating rates of change, with allowance for the
correlation structure of repeated measurements.17 In
analysis, the dependant variable was change in post-
bronchodilation forced expiratory volume in 1 s (FEV1)
expressed either as a percentage of the predicted value
or in millilitres (ml) logarithmically transformed, adjusting
for age, height, sex and baseline lung function. Initially,
unconditional growth models were ﬁtted in order to
describe net variation in slope and intercept between
individuals. Subsequently, conditional analyses were
undertaken in which systematic inter-individual dif-
ferences in intercept and slope were examined as a
function of the binary ﬁxed effect representing frequent/
infrequent exacerbations, adjusting for smoking status.
Power analysis based on sample size gave a power of over
80% to detect a difference of 1 percentage unit between
two groups, based on 5 repeated measurements, variance
500 and a correlation of about 0.9 between respective
measurements.
Smokers and ex-smokers were also considered as sepa-
rate groups. Full maximum likelihood estimation was used
in all models and improvement in model ﬁt was assessed
using Akaike’s information criterion (AIC). Fixed effects
were tested for statistical signiﬁcance using t-statistics.
Model ﬁt was assessed using plots of levels 1 and 2
standardized residuals against ﬁtted values. The lme func-
tion in the nlme package in the R environment (R versus 1.7)
was used.18
Analysis was repeated stratifying the patients into two
groups according either to the median rates of reported
exacerbations or, of medical records identiﬁed exacerba-
tions. Similar results were obtained and therefore are not
presented in detail.
Results
Baseline characteristics of participants are presented in
Table 1. According to the GOLD severity of COPD 22(21.5%)
patients were stages 0–I, 33(32.5%) were stage II, 29(28.5%)
were stage III, 18(17.5%) were stage IV. Six subjects were
lost to follow up and 13 died during the 3-year study period.
These subjects were at baseline of similar age, FEV1
(%pred), and smoking status to those who completed more
than ﬁve spirometric assessments (P40:05). The partici-
pants recorded their symptoms on the diary cards for
median(IQR) 720(720–1080) days. There was no signiﬁcant
difference in compliance rates of the diary cards between
frequent and infrequent exacerbators (Mann–Whitney
U-test, P ¼ 0:83).
There were available 597 spirometric assessments for
analysis which are less than scheduled because of patient
withdrawals, missing assessments or, exacerbations. Fre-
quent exacerbators performed mean(95% CI) 5.2(5.6–5.9)
spirometric tests and infrequent exacerbators 4.5(5.1–6)
(P ¼ 0:12).
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Table 1 Baseline characteristics of 102 COPD patients, overall and by smoking status.
Overall Ex-smokers Current smokers P-value**
n ¼ 102 n ¼ 58 n ¼ 44
Age (years) 65 (1.0) 68.5 (1.0) 62 (1.6) 0.002
Male/female 86/16 51/7 35/9 NS
FEV1 (%pred)* 56.4 (2.2) 52.4 (2.9) 61.8 (3.2) 0.047
Pack-years 52.7 (2.3) 55 (3.4) 49 (2.9) NS
FEV1/FVC (%) 55 (1.5) 54 (2.1) 57.9 (2.2) NS
MRC score 1 (0–4) 2 (0–4) 1 (0–3) NS
Chronic cough, n (%) 68 (66.6) 38 (65) 30 (68) NS
Chronic sputum, n (%) 48 (47) 28 (49) 20 (45.5) NS
Chronic wheeze, n (%) 33 (32) 19 (33) 14 (32) NS
Inhaled steroids, n (%) 38 (37) 22 (38) 16 (36) NS
Inhaled LABAs, n (%) 39 (38) 23 (40) 16 (36) NS
Continuous data are expressed as mean (SE), MRC score are presented as median (min–max) unless otherwise indicated. NS ¼ non-
signiﬁcant (P40:05), MRC ¼ Medical Research Council, LABAs ¼ long acting beta 2 agonists.
*Post-bronchodilation value.
**Current and ex-smokers characteristics were compared using the Mann–Whitney test (for continuous variables) or w2 test (for
categorical data), as appropriate.
D. Makris et al.1308Exacerbations
Ninety-ﬁve (93%) patients experienced at least one exacer-
bation over the 3-year study period. The overall median
(mean(95%CI)) annual exacerbation rate was 2.85 (3.1
(2.7–3.6)). The exacerbation rates were 3 (3.3 (3–3.9)), 3
(2.8 (2.5–3.2)) and 2 (2.3 (1.8–2.8)) for the ﬁrst, second and
third year, respectively. About 81% of total exacerbations
were recorded on the diary cards; 19% of total exacerbations
were not recorded on the cards and were identiﬁed from the
medical records (outpatient clinics and admissions).
There were no signiﬁcant differences in the exacerbation
rate between smokers and ex-smokers (Fig. 2). Baseline
characteristics of COPD patients according to exacerbation
status are presented in Table 2. Frequent exacerbators had
signiﬁcantly lower baseline FEV1% compared to infrequent
exacerbators (51.8% versus 60.2%, Mann–Whitney U-test,
P ¼ 0:048), although no differences in the main treatment
modalities (long acting beta-2 agonists and/or inhaled
corticosteroids) used in frequent and infrequent exacer-
bators (w2, P40:05) were observed. The GOLD severity scale
of the disease was associated with the number of exacer-
bations and the number of admissions to hospital (Kruskal–
Wallis, P-values 0.007 and 0.0005, respectively).
Additionally, the annual hospital-admission rate due to
severe exacerbations was 0.35 (0.27–0.42). The number of
admissions was correlated with the number of exacerbations
of each patient (r ¼ 0.6, P ¼ 0:001). The duration of
hospitalisation (days) was longer in frequent than in
infrequent exacerbators 7.3(6.1–8.5) versus 4.3(3.5–5.1),
respectively, P ¼ 0:045).Lung function decline
The mean annual rate of FEV1 (%pred) decline
(DFEV1,%pred/year) of the entire group was 2.6 (95% CI
2.2, 3.0, t ¼ 7:33, Po0:0001) corresponding to an absolutevalue of 74ml/year. REM analysis revealed that the annual
rate of decline was signiﬁcantly higher in smokers compared
to ex-smokers and the estimated effect of smoking,
adjusting for exacerbation status, added to the 3-year
average decline in FEV1 (%pred) 1.8 (2.1, 1.5)
percentage units per year (P ¼ 0:004).
There was a signiﬁcant interaction between FEV1 decline
and exacerbation frequency (Fig. 3). REM analysis revealed
that DFEV1, %pred/year was signiﬁcantly higher in frequent
exacerbators than in infrequent exacerbators, controlling
for smoking status. The estimated effect of frequent
exacerbations added to DFEV1, %pred/year 1.4 (1.05,
1.75) percentage units (P ¼ 0:017).
When REM was applied for frequent and infrequent
exacerbators in each smoking category, a statistically
signiﬁcant decrease in FEV1 over the 3-year period was seen
in each category, but not in ex-smokers infrequent exacer-
bators (Table 3).
The analyses were repeated using the log-transformed
FEV1 values (ml). The results were very similar to the above
and therefore are not presented in detail.
Discussion
In this investigation, we evaluated the interaction between
FEV1 and COPD exacerbations in a population consisting of
102 patients with COPD of varying severity for a total of
3-year follow-up period. The main ﬁndings of this study are
(i) COPD patients with frequent exacerbations showed a
higher rate of decline in FEV1 compared to patients with
infrequent exacerbations, (ii) the highest rate of decline in
FEV1 was demonstrated in smokers who are frequent
exacerbators, and (iii) although the data of this study
suggest that smoking is a major determinant of the lung
function decline in COPD, the novel point is the considerable
interaction between exacerbation frequency and lung
function decline in COPD even in ex-smokers. These ﬁndings
support previous studies reporting that increased frequency
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Table 2 Baseline characteristics of frequent (Xmedian annual exacerbation rate) and infrequent exacerbators (omedian
annual rate).
Frequent exacerbations Infrequent exacerbations P-value
n ¼ 51 n ¼ 46
Age (years) 67 (3) 63 (2.5) NS
Male/female 42/9 39/7 NS
Current smokers/ex-smokers 22/29 19/27 NS
Pack-years 55 (3) 49 (4) NS
FEV1 (%pred)
y 51.8 (3) 60.2 (3) 0.048
FEV1/FVC (%) 52.5 (2) 58.5 (2) NS
MRC score, median (min–max) 2 (1–4) 1 (0–3) 0.005
Chronic cough, n (%) 40(78) 24(52) 0.005
Chronic sputum, n (%) 26(51) 19 (41) NS
Chronic wheeze, n (%) 18(35) 12(26) NS
Respiratory symptoms at baselinez 39 (76) 23 (50) 0.005
Inhaled steroids, n (%) 16 (31) 21 (45) NS
Inhaled LABAs, n (%) 15 (29) 22 (47) NS
Continuous data are expressed as mean (SER) unless otherwise indicated. NS ¼ non-signiﬁcant (P40:05), MRC ¼ Medical Research
Council, LABAs ¼ long acting beta 2 agonists.
Current and ex-smokers characteristics were compared using the Mann–Whitney test (for continuous variables) or w2 test (for
categorical data), as appropriate.
yPost-bronchodilation value.
zAt least two out of the following four symptoms were present: cough, sputum, MRC dyspnea score X2, wheezing.
p=0.007*
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Figure 2 COPD exacerbations during the 3-year study period
according to GOLD stages. *Difference between GOLD stage of
disease severity.
Exacerbations and lung function in COPD 1309of exacerbations is signiﬁcantly associated with FEV1
decline.7,8
This study has limitations. First, the deﬁnition of COPD
exacerbation is still under discussion and no consensus exists
for the identiﬁcation of exacerbations.3,7,19,20 However, we
used the generally accepted deﬁnition of Anthonisen’s et
al.15 and on baseline, we evaluated baseline patients’ status
using previously validated questionnaires.11,12 Second, it is
known that COPD patients have a low perception of
dyspnoea and underreport exacerbations to physicians.21 In
order to increase the accuracy of the diagnosis of an
exacerbation, we used daily records data of respiratory
symptoms. This is an accepted methodology for the
assessment of COPD exacerbations in terms of symptoms.8,21Despite the fact that collecting daily prospective data on
symptom changes is rather difﬁcult to be applied widely in
the everyday clinical practice, it offers the advantage that
episodes when patients experience an exacerbation and
record their symptoms but do not consult their physician can
be analysed. In this way, we found a median annual
exacerbation rate of 2.85 (mean 3.1) which is similar to
previously reported rates where diary cards were used8 and
higher than the reported rates when symptoms questioning
alone was used.7,20 Some might argue that the criteria used
in this study for deﬁnition, onset and resolution of
exacerbations are subjective, not ‘‘solid’’ and therefore of
low clinical importance because they depend on patients
reports of symptoms. However, these criteria are applied
widely in medical practice and previous studies used similar
methodology.8,15,22,23
The main endpoints of this study were assessed at 3- and
6-month intervals, during the 3-year follow-up period.
Despite that a 3-year period is a relatively short time period
in the course of the disease, it is a sufﬁcient period for
statistical evaluation. In addition, the primary aim of the
lung function modelling procedures presented here was to
assess the rate of change in FEV1 with time rather than focus
on absolute FEV1 values. Furthermore, the use of daily cards
for the diagnosis of exacerbations requires patient’s
compliance that may decrease with time. Thus, we believe
that the 3-year follow-up period of this study was a
reasonable duration for balancing diagnostic accuracy and
compliance.
It might be implying that although we are seeing high
rates of decline in frequent exacerbators, this may be
because they have lower baseline values and not because
they are frequent exacerbators. We believe that this was
not the case in the present study. In order to control further
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Table 3 Average annual FEV1 decline (%pred)
 over the 3-year-study period obtained using random effects modelling, for all
COPD patients, smokers and ex-smokers separately, by exacerbation status.
Exacerbation status Smokers Ex-smokers
n Mean 95% CI n Mean 95% CI
Frequent exacerbations
(Xmedian annual rate)
22 4.10 (4.40,
3.80)
Po0:0001 29 2.80 (3.1,
2.5)
Po0:0001
Infrequent exacerbations
(omedian annual rate)
19 3.15 (3.55,
2.75)
P ¼ 0:002 27 0.85 (1.1,
0.5)
P ¼ 0:3
Adjusted for sex, age, smoking status, baseline FEV1 (%pred).
Figure 3 FEV1(%pred) change from baseline over the 3-year
study period by total exacerbation status. Values are means
with bars representing SE and numbers in brackets reﬂect
patients with valid readings at each time point. *Difference in
average annual decline rate in FEV1(%pred) between frequent
and infrequent exacerbators, obtained by REM.
D. Makris et al.1310for the ‘‘horse-racing effect’’, we have modelled the
complete FEV1 growth trajectory (intercept and rate of
change) of each individual and have assessed differences in
rates of change over time, whilst also accounting for
possible differences in baseline values between groups.
Furthermore, to ensure that baseline FEV1 are not too
different between groups we classiﬁed the study population
into relatively homogeneous groups (GOLD) and then
applying the REM.
The progressive decline of lung function reported in our
COPD patients is greater than that reported in the general
population.4 However, there is considerable intersubject
variation in the rate of FEV1 decline, depending on the
population studied. For example, Simmons et al.24 reported
rates of 60–100ml/year among smokers with mild-to-
moderate COPD while the ISOLDE study reported 50 and
59ml/year decline in FEV1 in ﬂuticasone treated and
placebo groups, respectively.25 In the present study, the
estimated overall mean FEV1 decline was 74ml/year but our
sample may be more homogenous in terms of race-ethnicity
since all patients were white Greeks living in the island ofCrete and in their vast majority male. In addition our
population represented mainly COPD patients followed at a
specialist hospital clinic. In this respect, it is reasonable to
consider that less symptomatic patients were probably not
referred to the clinic.26 This could be also a plausible
explanation for the fact that ex-smokers had similar cough,
sputum production and use of medication as the continuous
smokers in this study. On the other hand this population is
probably more heterogeneous than those of other studies
with respect to baseline disease severity, smoking status and
particularly treatment modalities; for instance a total of
38% of our patients were treated with inhaled steroids.
Therefore, the conclusions drawn in the present investiga-
tion should be rather applied to male COPD patients with
increased respiratory symptoms than to the general COPD
population.
The present study shows that frequent exacerbations are
associated with an accelerated loss of FEV1 compared to
infrequent exacerbations. Our ﬁndings is in accordance with
previous studies,7,8,27 although their design was different
from our study in terms of the population studied and
outcome assessment. Donaldson et al.8 prospectively fol-
lowed 109 COPD patients for 4 years based on diary cards,
but the assessment of FEV1 decline was made on a subgroup
of 32 patients of their cohort. Kanner et al.7 found an
accelerated FEV1 decline only in smokers with frequent
exacerbations. However, they assessed exacerbation only by
questioning their participants annually, and their group
comprised relatively young individuals with early COPD.
These reasons could explain the low reported exacerbation
rate (0.24 year1) in the latter study. Dowson et al.27 found a
signiﬁcant interaction between exacerbation frequency and
lung function decline in terms of vital capacity and diffusing
capacity of the lung for carbon monoxide but not with FEV1.
However, their data derived exclusively from patients with
a1-antitrypsin-deﬁciency and exacerbation data were mainly
collected at 6-month assessment.
In agreement with other studies,7,28 the smokers in this
study had a more rapid FEV1 decline, particularly those with
frequent exacerbators. Smoking is known to be associated
with both increased airway inﬂammation and accelerated
rate of FEV1 decline.
4,29 However, the inﬂammatory mani-
festation of current smoking may mask the underlying
ongoing inﬂammatory process characterizing COPD.30 Pre-
vious studies have shown that airway inﬂammation induced
by smoke may persist independently from smoking.29,31
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Exacerbations and lung function in COPD 1311A notable observation of our study is that COPD ex-
smokers with frequent exacerbations exhibited a signiﬁ-
cantly increased rate of FEV1 decline. In contrast, ex-
smokers infrequent exacerbators exhibited no signiﬁcant
loss of lung function. This is of importance because the
course of the disease in patients with advanced COPD is not
well deﬁned, particularly in patients quitting smoking.32 In a
previous study, Kanner and colleagues7 found no signiﬁcant
interaction between exacerbations and FEV1 in subjects who
quitted smoking. However, their data were derived from a
population with early COPD (mean FEV1 78.2%pred) and low
exacerbation frequency. Thus, we believe that in our cohort
of COPD patients with advanced disease, a higher frequency
of exacerbations was signiﬁcantly associated with a negative
impact on FEV1 decline even in ex-smokers.
It should be underlined here that this signiﬁcant associa-
tion between exacerbations and FEV1 decline does not prove
a causal relationship. Increased frequency of exacerbations
may directly accelerate loss of FEV1, but the opposite could
be also possible: loss of lung function may lead to increased
exacerbation frequency. In this respect, a randomized
longitudinal clinical intervention study is necessary to assess
deﬁnitively whether or not frequent exacerbations are the
cause of an accelerated rate of lung function decline.
However, our ﬁndings still suggest a positive feedback
involving frequency of exacerbations and FEV1 decline and
that a common pathway for both these two important
parameters is possible. Furthermore, the positive associa-
tion between lung function decline and exacerbation
frequency suggests a considerable negative impact of
exacerbations on health status and costs. Especially, if one
considers that patients with impaired lung function experi-
ence also more severe exacerbations.33
In summary, although the data suggest that continuing
smoking is the major determinant of accelerating loss of
lung function, an increased frequency of exacerbations
appears also to be associated with an accelerate rate of lung
function decline. Thus, therapies that have an impact upon
exacerbation frequency may modify chronic obstructive
pulmonary disease progression in terms of lung function and
overall health status. Physicians in charge of patients with
COPD should encourage early reporting of all exacerbations
in this patient group and they should be alert to offer them
prompt therapy. In COPD, not only smoking cessation but
also a decrease frequency of exacerbations should be a
major target of management.References
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